I am sorry that I don't take the opportunity to post....but

New Post Public Reply Private Reply Replies (0) Message Board
carpediemdriver
744
I am sorry that I don't take the opportunity to post....but for the most part you have been incredibly helpful, informative and supportive over the many years I have been following this company and reading your post on a daily basis for many years. I want to truly thank everyone who continues to support our investment in IPIX by providing truthful informative information that has enabled me to deepen my belief and strengthen my knowledge base with regards to the science and my investment that will eventually lead us toward success we all hope to have.

As we look forward into the path towards the approval of Brilacidin I believe it's important to also have a realistic perspective regarding the many challenges that we might face within the approval process. It's important to be aware of the environment that we are dealing with and this podcast I came across was very informative. Many of you probably already know this and maybe have already seen this podcast but if not I think everyone invested in Biotech at this time should be aware of these issues.... so please take a few min to watch this podcast... BIG PHARMA'S Ties To The FDA Should Be Questioned
https://www.youtube.com/watch?v=EQYHx7drUWE

I don't believe in conspiracy theories but I thought that this was a very good somewhat balanced and informative podcast uncovering the many huge current conflicts of interest within the FDA and BP regarding FDA funding, drug approval history, the approval process ie. clinical trails design favoring drug approval, advisory Committee conflicts of interest and in return possibly why some drugs because of lack of funding, support etc,,are not approved. Basically we have a regulatory body funded by the same company's that the regulatory body is tasked to regulate....creating huge conflicts of interest on every level of the drug approval process.
It also addressed how the FDA & CDC during the Covid Pandemic has not been able to work as efficiently and effectively as it could have during a pandemic possibly costing many lives. Also near the en at 9:15min mark they touched on a past issue... in that there were drugs ie therapeutics for HIV in the past that were given an EUA but even after 20 years were not ever approved that could've saved lives.

Please understand that I am not sharing this post in an effort to bring about discussions and debates regarding the FDA because these are issues that we realistically don't have control over and I do not want to waste time discussing and debating these issues with this regard but only to make sure we are aware of them....Regardless I am hoping and praying everyday that the trail will be incredibly successful as possible because I know Brilacidin can put an end to this pandemic and possibly all others in the future... BUT I also am trying to be realistic with regards to the many challenges that we might face within the approval process especially as I continue to review and become aware of the many road blocks and challenges other companies are currently facing during their path towards EUA's and drug approvals. So it's something to watch out for and pray that we can and will overcome these challenges because of our incredible unquestionable efficiency and safety history.

I hope everyone has a blessed weekend as we anxiously await for results of the trail that can change the future of medicine as we know it today.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

BexBack Offers Revolutionary 100x Leverage Crypto Trading

Updated Category News Views 136

Transform Your Crypto Trading Experience with BexBack In the rapidly evolving world of cryptocurrency trading, events can significantly impact market dynamics. BexBack Exchange, a prominent platform, is at the forefront of change by introducing a no KYC, 100x leverage trading option. This innovative structure comes alongside an enticing double deposit bonus and a $50...

Continue Reading
Landmark Bancorp Plans Earnings Call for Q3 2024 Results

Updated Category News Views 56

Landmark Bancorp to Host Conference Call for Earnings Discussion Landmark Bancorp, Inc. (Nasdaq: LARK) is set to release its earnings report for the third quarter of 2024 following market closure on a Wednesday. This upcoming announcement is highly anticipated by investors and stakeholders who keep a keen eye on the company's performance and insights. Details of the...

Continue Reading
AT&T Presents Final Offer to CWA Union Amidst Strike

Updated Category News Views 66

AT&T's New Proposal to CWA Union Telecom giant AT&T (NYSE: T) has taken a significant step by presenting its final offer to the Communications Workers of America (CWA) bargaining committee. This development occurs amidst ongoing negotiations and a strike involving over 17,000 employees, including technicians and customer service representatives. Details of the Final Offer...

Continue Reading
Aspen Aerogels Shows Adaptability Amid Changing Market Trends

Updated Category News Views 133

Aspen Aerogels Demonstrates Resilience in Financial Results Recent awards indicate growth potential & strategic advancements in energy solutions. Aspen Aerogels, Inc. (NYSE: ASPN), a company known for its pioneering efforts in sustainability and electrification technology, has released its financial results for the third quarter of 2025. The company's adaptability in...

Continue Reading
Great Elm Capital Corp. Updates on Third Quarter Earnings Call

Updated Category News Views 124

Great Elm Capital Corp. Announces Third Quarter Earnings Release Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) has exciting news for investors and stakeholders. They have scheduled the release of their third-quarter financial results following the close of trading on a Tuesday in early November. This briefing brings together key stakeholders to...

Continue Reading